Objective  This study's objective was to understand the epidemiologic profile of the patients with inflammatory bowel disease in the state of Tocantins, Brazil. Methods  This is a descriptive study of secondary data, which was gathered by using the Informatics Department of the Brazilian Health System, and it corresponds to the cases registered from January of 2010 to December of 2017. The data of interest were those related to the total number of admissions, age range, gender, ethnicity, city of hospitalization, and type of care. Results  There were 340 hospital admissions due to inflammatory bowel diseases in Tocantins, of which 204 (60%) were female patients and 136 (40%), male patients; the predominant age group was between 20 and 59 years old (65.88%). These hospitalizations lasted an average of 4.7 days and 98.23% of them occurred as a matter of urgency. Conclusion  The study demonstrated that the epidemiological profile of the inflammatory bowel disease in the state of Tocantins consists of female patients, aged between 20 and 59 years, with hospitalizations lasting 4.7 days and mainly urgent, demonstrating that it is necessary to implement screening measures in order to make the diagnosis earlier, thus preventing possible complications.

Acute pancreatitis (AP) is an inflammatory disease associated with abdominal pain and elevated serum pancreatic enzymes. The most common etiologies are gallstones and alcoholism. Drug-induced AP is quite rare, lacks a solid understanding and has been occasionally reported. The diagnosis requires a great suspicion and a careful exclusion of other causes. We present a case of a 37-year-old man, previously diagnosed with leprosy that developed acute pancreatitis after starting the multibacillary polychemotherapy (PCT/MB). After a month of treatment and the discontinuation of the PCT/MB, the therapy was restarted and a new episode of AP occurred. Three months after this last episode, the PCT/MB was reintroduced, changing one of the medications and the patient had no recurrence of AP or other reactions. Therefore, it is important to take into account that there is a risk of acute pancreatitis in patients on multidrug therapy (MDT) for leprosy.

O SARS-CoV-2, que causa a patologia conhecida como COVID-19, foi identificado em dezembro de 2019 como a causa de uma série de casos de pneumonia na cidade chinesa de Wuhan. O número de casos aumentou consideravelmente nos meses subsequentes e a Organização Mundial da Saúde (OMS) declarou no dia 11 de março de 2020 a pandemia de COVID-19. Trata-se de um vírus de RNA, envelopado e que possui uma alta taxa de transmissão.  A apresentação clínica pode variar de um quadro assintomático ou leve, até casos graves que cursam com insuficiência respiratória. Febre, tosse, dispneia, fadiga, mialgia generalizada e cefaleia são os sintomas comumente observados. Até a data de realização desse estudo, não haviam terapias específicas que tenham apresentado eficácia claramente comprovada. O objetivo desse artigo foi abordar diversos aspectos sobre o SARS-CoV-2, incluindo a epidemiologia, quadro clínico, diagnóstico e tratamento da COVID-19. Realizou-se uma revisão sistemática da literatura, com o uso da base de dados do Pubmed e relatórios do Ministério da Saúde do Brasil e da OMS, que resultou na seleção de 77 referências baseadas no Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).